Amplify Seymour Cannabis ETF
  
Schedule of Investments
  
as of June 30, 2024 (Unaudited)
  
   
COMMON STOCKS - 43.9%
  
Shares
    
Value
  
Consumer Discretionary - 3.7%
        
GrowGeneration Corp.(a)
    
519,269
    
$
1,116,428
  
                 
Consumer Staples - 2.0%
          
Village Farms International, Inc.(a)(b)
    
603,288
      
615,354
  
                 
Financials - 3.3%
          
Silver Spike Investment Corp.
    
82,918
      
981,749
  
                 
Health Care - 30.2%(c)
          
Aleafia Health, Inc.(a)(d)
    
80,872
      
0
  
Auxly Cannabis Group, Inc.(a)
    
3,257,044
      
71,424
  
Canopy Growth Corp.(a)(b)
    
37,681
      
243,043
  
Cara Therapeutics, Inc.(a)
    
68,078
      
17,564
  
Charlotte's Web Holdings, Inc.(a)(b)
    
1,145,407
      
226,059
  
Clever Leaves Holdings, Inc.(a)
    
5,288
      
13,960
  
Cronos Group, Inc.(a)
    
544,484
      
1,268,648
  
Curaleaf Holdings, Inc.(a)
    
731,495
      
2,807,170
  
Jazz Pharmaceuticals PLC(a)
    
573
      
61,156
  
MediPharm Labs Corp.(a)
    
2,927,844
      
160,512
  
Organigram Holdings, Inc.(a)(b)
    
176,380
      
271,625
  
SNDL, Inc.(a)
    
310,370
      
589,703
  
TerrAscend Corp.(a)
    
1,018,710
      
1,385,038
  
Tilray Brands, Inc.(a)(b)
    
1,214,084
      
2,015,379
  
             
9,131,281
  
                 
Industrials - 0.4%
          
Hydrofarm Holdings Group, Inc.(a)
    
178,296
      
123,024
  
                 
Information Technology - 4.3%
          
WM Technology, Inc.(a)
    
1,261,458
      
1,311,916
  
TOTAL COMMON STOCKS (Cost $69,968,008)
      
13,279,752
  
                 
REAL ESTATE INVESTMENT TRUSTS - 8.5%
                
Chicago Atlantic Real Estate Finance, Inc.
    
31,160
      
478,618
  
Innovative Industrial Properties, Inc.
    
19,134
      
2,089,815
  
TOTAL REAL ESTATE INVESTMENT TRUSTS (Cost $2,206,047)
      
2,568,433
  
                 
RIGHTS - 0.0%(e)
  
Contracts
          
Health Care - 0.0%(e)
          
Harmony Biosciences Holdings, Inc., Expires 10/12/2024, Exercise Price $2.54(a)(d)
    
220,858
      
0
  
TOTAL RIGHTS (Cost $0)
      
0
  
                 
SHORT-TERM INVESTMENTS - 19.2%
                
Investments Purchased with Proceeds from Securities Lending - 10.7%
  
Shares
          
First American Government Obligations Fund - Class X, 4.65%(f)
    
3,230,545
      
3,230,545
  
                 
Money Market Funds - 8.5%
                
Invesco Government & Agency Portfolio - Institutional Class, 5.25%(f)
    
2,554,152
      
2,554,152
  
TOTAL SHORT-TERM INVESTMENTS (Cost $5,784,697)
      
5,784,697
  
                 
TOTAL INVESTMENTS - 71.6% (Cost $77,958,752)
    
$
21,632,882
  
Other Assets in Excess of Liabilities - 28.4%
      
8,562,300
  
TOTAL NET ASSETS - 100.0%
          
$
30,195,182
  
               
Percentages are stated as a percent of net assets.
          
   
The Global Industry Classification Standard ("GICS®") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.
  

PLC - Public Limited Company

(a)
Non-income producing security.
(b)
All or a portion of this security is on loan as of June 30, 2024. The total market value of these securities was $2,642,817 which represented 8.8% of net assets.
(c)
To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors.
(d)
Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Adviser, acting as Valuation Designee. These securities represented $0 or 0.0% of net assets as of June 30, 2024.
(e)
Represents less than 0.05% of net assets.
(f)
The rate shown represents the 7-day effective yield as of June 30, 2024.


Amplify Seymour Cannabis ETF
Schedule of Total Return Swap Contracts
as of June 30, 2024 (Unaudited)
 
Reference Entity
  
Counterparty
  
Long/Short
  
Maturity Date
  
Financing Rate(a)
  
Payment Frequency
  
Notional Amount
    
Value/ Unrealized
Appreciation
(Depreciation)
Ayr Wellness, Inc. Warrant Expires 02/07/2026
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
$70,367
    
$2,731
Ayr Wellness, Inc.
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 489,043
    
 15,880
Cannabist Company
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 56,636
    
 2,934
Cresco Labs, Inc.
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 1,851,435
    
 (62,570)
Curaleaf Holdings, Inc.
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 551,863
    
 (24,133)
Green Thumb Industries, Inc.
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 4,224,365
    
 58,278
Truelieve Cannabis Corp.
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 3,918,393
    
 161,632
Verano Holdings Corp.
  
Nomura Securities International, Inc.
  
Long
  
06/26/2025
  
6.82%
  
Monthly
  
 2,097,247
    
 110,074
Total Unrealized Appreciation (Depreciation)
                   $
 264,826
                       
There are no upfront payments or receipts associated with total return swaps in the Fund as of June 30, 2024.

(a) Floating rate based on the overnight bank rate and spread of 150 basis points and is reset monthly.


Summary of Fair Value Disclosure as of June 30, 2024 (Unaudited)
 
Amplify Seymour Cannabis ETF has adopted authoritative fair value accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.
 
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.
 
Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
 
Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.
 
The following is a summary of the fair valuation hierarchy of the Fund’s securities as of June 30, 2024:

   
Level 1
    
Level 2
    
Level 3
    
Total
  
Assets:
                        
  Common Stocks
    
13,279,752
      
–
      
0
(a) 
    
13,279,752
  
  Real Estate Investment Trusts
    
2,568,433
      
–
      
–
      
2,568,433
  
  Rights
    
–
      
–
      
0
(a) 
    
0
(a) 
  Investments Purchased with Proceeds from Securities Lending
    
3,230,545
      
–
      
–
      
3,230,545
  
  Money Market Funds
    
2,554,152
      
–
      
–
      
2,554,152
  
Total Investments
    
21,632,882
      
–
      
0
(a) 
    
21,632,882
  
   
Other Financial Instruments*:
                                
  Total Return Swaps
    
–
      
351,529
      
–
      
351,529
  
Total Other Financial Instruments
    
–
      
351,529
      
–
      
351,529
  
                                 
Liabilities:
                                
Other Financial Instruments*:
                                
  Total Return Swaps
    
–
      
(86,703
)
    
–
      
(86,703
)
Total Other Financial Instruments
    
–
      
(86,703
)
    
–
      
(86,703
)
   
* The fair value of the Fund's investment represents the net unrealized appreciation (depreciation) as of June 30, 2024.
  
   
Refer to the Schedule of Investments for additional information.
  

(a)
Amount is less than $0.50.

For the period ended June 30, 2024, there were the following transfers into or out of Level 3 for the Fund. Below is a reconciliation of securities in Level 3 for the Fund.
CNBS
  
Balance as of 10/31/2023
    
Amortization/
Accretion
    
Net Realized Gain (Loss)
    
Net Change in Unrealized Appreciation (Depreciation)
    
Purchases/
Acquisition
    
Sales
    
Corporate Action
    
Transfer In/Out of Level 3
    
Balance as of 06/30/2024
    
Net Change in
Unrealized
Appreciation (Depreciation)
on Securities
held at
06/30/2024
  
Common Stocks
  
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
0
    
$
0
  
Rights
  
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
0
    
$
0
  
The following is a summary of quantitative information about Level 3 Fair Value Measurements:
          

CNBS
  
Fair Value as of
06/30/2024
  
Valuation Techniques
Unobservable Input
  
Range/Weighted
Average
Unobservable Input
  
Impact to Valuation from
an Increase to Input
Common Stocks (Aleafia Health Inc)
  

$0
  
Market Approach
No Market Activity
    
-
  
Increase
Rights (Harmony Biosciences Holdings Inc)
  

$0
  
Market Approach
No Market Activity
    
-
  
Increase
CNBS
  
Fair Value as of
06/30/2024
  
Valuation Techniques
Unobservable Input
  
Range/Weighted
Average
Unobservable Input
  
Impact to Valuation from
an Increase to Input
Common Stocks
  

$-
  
Market Approach
No Market Activity
    
-
  
Increase
Rights
  

$-
  
Market Approach
No Market Activity
    
-
  
Increase


Secured Borrowings (Unaudited)
The Funds adopted guidance requiring entities to present gross obligations for secured borrowings by the type of collateral pledged and remaining time to maturity.

As of June 30, 2024, the Fund had loaned securities and received cash collateral for the loans. The cash collateral is invested by the Securities Lending Agent in accordance with approved investment guidelines. Those guidelines require the cash collateral to be invested in readily marketable, high quality, short-term obligations; however, such investments are subject to risk of payment delays or default on the part of the issuer or counterparty or otherwise may not generate sufficient interest to support the costs associated with securities lending. The Fund could also experience delays in recovering its securities and possible loss of income or value if the borrower fails to return the borrowed securities, although the Fund is indemnified from this risk by contract with the Securities Lending Agent.